modelBempedoicAcid
Extends from Pharmacolibrary.Drugs.ATC.C.C10AX15.
Information
| name: | BempedoicAcid | |
| ATC code: | C10AX15 | route: | oral |
| compartments: | 1 | |
| dosage: | 180 | mg |
| volume of distribution: | 18 | L |
| clearance: | 11.2 | L/h |
| other parameters in model implementation | ||
Bempedoic acid is an oral adenosine triphosphate-citrate lyase (ACL) inhibitor used to lower LDL cholesterol levels in adults with hypercholesterolemia or established atherosclerotic cardiovascular disease. It is approved for clinical use as an adjunct to diet and maximally tolerated statin therapy.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects after oral administration.
References
Jadhav, SB, et al., & Emery, MG (2023). Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia. Journal of pharmacokinetics and pharmacodynamics 50(5) 351–364. DOI:10.1007/s10928-023-09864-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/37243877
Amore, BM, et al., & Emery, MG (2023). Phase 1, Single- and Multiple-Ascending-Dose, Food-Effect, and East Asian Subject Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Bempedoic Acid, a Selective Inhibitor of Adenosine Triphosphate Citrate Lyase. Clinical pharmacology in drug development 12(10) 1022–1035. DOI:10.1002/cpdd.1297 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37477389
Stoll, F, et al., & Blank, A (2025). Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers. Pharmaceutics 17(1) –. DOI:10.3390/pharmaceutics17010060 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39861708
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)